209 related articles for article (PubMed ID: 24852853)
1. Circulating free DNA in a screening program for early colorectal cancer detection.
Perrone F; Lampis A; Bertan C; Verderio P; Ciniselli CM; Pizzamiglio S; Frattini M; Nucifora M; Molinari F; Gallino G; Gariboldi M; Meroni E; Leo E; Pierotti MA; Pilotti S
Tumori; 2014; 100(2):115-21. PubMed ID: 24852853
[TBL] [Abstract][Full Text] [Related]
2. KRAS mutations and M2PK upregulation in stool samples from individuals with positive fecal occult blood tests screened for colorectal cancer.
Battaglia P; Baritono E; Remo A; Vendraminelli R; Conti A
Tumori; 2014; 100(2):122-7. PubMed ID: 24852854
[TBL] [Abstract][Full Text] [Related]
3. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
[TBL] [Abstract][Full Text] [Related]
4. Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma.
Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
Int J Cancer; 2014 Nov; 135(9):2215-22. PubMed ID: 24659028
[TBL] [Abstract][Full Text] [Related]
5. High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients.
Allenson K; Castillo J; San Lucas FA; Scelo G; Kim DU; Bernard V; Davis G; Kumar T; Katz M; Overman MJ; Foretova L; Fabianova E; Holcatova I; Janout V; Meric-Bernstam F; Gascoyne P; Wistuba I; Varadhachary G; Brennan P; Hanash S; Li D; Maitra A; Alvarez H
Ann Oncol; 2017 Apr; 28(4):741-747. PubMed ID: 28104621
[TBL] [Abstract][Full Text] [Related]
6. Early Detection of Colorectal Cancer: a Multi-Center Pre-Clinical Case Cohort Study for Validation of a Combined DNA Stool Test.
Dollinger MM; Behl S; Fleig WE
Clin Lab; 2018 Oct; 64(10):1719-1730. PubMed ID: 30336540
[TBL] [Abstract][Full Text] [Related]
7. Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan.
Spindler KL; Pallisgaard N; Vogelius I; Jakobsen A
Clin Cancer Res; 2012 Feb; 18(4):1177-85. PubMed ID: 22228631
[TBL] [Abstract][Full Text] [Related]
8. Multitarget stool DNA testing for colorectal-cancer screening.
Imperiale TF; Ransohoff DF; Itzkowitz SH; Levin TR; Lavin P; Lidgard GP; Ahlquist DA; Berger BM
N Engl J Med; 2014 Apr; 370(14):1287-97. PubMed ID: 24645800
[TBL] [Abstract][Full Text] [Related]
9. KRAS and BRAF mutation analysis in colorectal adenocarcinoma specimens with a low percentage of tumor cells.
Lewandowska MA; Jóźwicki W; Żurawski B
Mol Diagn Ther; 2013 Jun; 17(3):193-203. PubMed ID: 23606169
[TBL] [Abstract][Full Text] [Related]
10. Detection of mutations in circulating cell-free DNA in relation to disease stage in colorectal cancer.
Liebs S; Keilholz U; Kehler I; Schweiger C; Haybäck J; Nonnenmacher A
Cancer Med; 2019 Jul; 8(8):3761-3769. PubMed ID: 31134762
[TBL] [Abstract][Full Text] [Related]
11. Optimization of circulating cell-free DNA recovery for KRAS mutation and HPV detection in plasma.
Mazurek AM; Fiszer-Kierzkowska A; Rutkowski T; Składowski K; Pierzyna M; Scieglińska D; Woźniak G; Głowacki G; Kawczyński R; Małusecka E
Cancer Biomark; 2013; 13(5):385-94. PubMed ID: 24440979
[TBL] [Abstract][Full Text] [Related]
12. The diagnostic accuracy of circulating free DNA for the detection of KRAS mutation status in colorectal cancer: A meta-analysis.
Xie W; Xie L; Song X
Cancer Med; 2019 Mar; 8(3):1218-1231. PubMed ID: 30791218
[TBL] [Abstract][Full Text] [Related]
13. [Immunophenotypes and gene mutations in colorectal precancerous lesions and adenocarcinoma].
Huang WT; Qiu T; Ling Y; Shi SS; Guo L; Zheng B; Lü N; Ying JM
Zhonghua Bing Li Xue Za Zhi; 2013 Oct; 42(10):655-9. PubMed ID: 24433726
[TBL] [Abstract][Full Text] [Related]
14. A new approach to epigenome-wide discovery of non-invasive methylation biomarkers for colorectal cancer screening in circulating cell-free DNA using pooled samples.
Gallardo-Gómez M; Moran S; Páez de la Cadena M; Martínez-Zorzano VS; Rodríguez-Berrocal FJ; Rodríguez-Girondo M; Esteller M; Cubiella J; Bujanda L; Castells A; Balaguer F; Jover R; De Chiara L
Clin Epigenetics; 2018; 10():53. PubMed ID: 29686738
[TBL] [Abstract][Full Text] [Related]
15. High-resolution melting assay (HRMA) is a simple and sensitive stool-based DNA Test for the detection of mutations in colorectal neoplasms.
Li BS; Wang XY; Xu AG; Ma FL; Ma QY; Li Z; Liu JH; Gan AH; Yu ZJ; Zhang XH; Jiang B
Clin Colorectal Cancer; 2012 Dec; 11(4):280-90. PubMed ID: 22609129
[TBL] [Abstract][Full Text] [Related]
16. Comparison of KRAS mutation analysis of primary tumors and matched circulating cell-free DNA in plasmas of patients with colorectal cancer.
Kuo YB; Chen JS; Fan CW; Li YS; Chan EC
Clin Chim Acta; 2014 Jun; 433():284-9. PubMed ID: 24685572
[TBL] [Abstract][Full Text] [Related]
17. Detection of tumor-derived cell-free DNA from colorectal cancer peritoneal metastases in plasma and peritoneal fluid.
Van't Erve I; Rovers KP; Constantinides A; Bolhuis K; Wassenaar EC; Lurvink RJ; Huysentruyt CJ; Snaebjornsson P; Boerma D; van den Broek D; Buffart TE; Lahaye MJ; Aalbers AG; Kok NF; Meijer GA; Punt CJ; Kranenburg O; de Hingh IH; Fijneman RJ
J Pathol Clin Res; 2021 May; 7(3):203-208. PubMed ID: 33635598
[TBL] [Abstract][Full Text] [Related]
18. KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer.
Xu JM; Liu XJ; Ge FJ; Lin L; Wang Y; Sharma MR; Liu ZY; Tommasi S; Paradiso A
J Exp Clin Cancer Res; 2014 Dec; 33(1):104. PubMed ID: 25491325
[TBL] [Abstract][Full Text] [Related]
19. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA.
Thierry AR; Mouliere F; El Messaoudi S; Mollevi C; Lopez-Crapez E; Rolet F; Gillet B; Gongora C; Dechelotte P; Robert B; Del Rio M; Lamy PJ; Bibeau F; Nouaille M; Loriot V; Jarrousse AS; Molina F; Mathonnet M; Pezet D; Ychou M
Nat Med; 2014 Apr; 20(4):430-5. PubMed ID: 24658074
[TBL] [Abstract][Full Text] [Related]
20. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].
Zhang X; Wang Y; Gao N; Wang J
Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
